Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026
Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026
Company Deals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Fineline Cube Mar 13, 2026
Company Deals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Fineline Cube Mar 13, 2026
Company Deals

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market

Fineline Cube Mar 13, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Fineline Cube Mar 13, 2026
Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Fineline Cube Mar 13, 2026
Company Deals

ChemPartner and Leado Pharma Sign Strategic Agreement to Advance New Drug R&D

Fineline Cube Aug 5, 2025

Shanghai ChemPartner Co., Ltd. (“ChemPartner”) and Shanghai Leado Pharma Co., Ltd. (“Leado Pharma”) have officially...

Company Deals

Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01

Fineline Cube Aug 5, 2025

China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng...

Company Medical Device

Gaush Meditech’s Frequency-Domain Biometer Gains Medical Device Registration in Jiangsu

Fineline Cube Aug 5, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) has recently obtained the medical device registration certificate for...

Company Drug

Sichuan Huiyu’s HY05350 Achieves First Patient Dosing in Phase I Trial for MSLN-Positive Tumors

Fineline Cube Aug 5, 2025

China-based Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced that its wholly-owned subsidiary, Huiyu Haiyue,...

Company Drug

Zhaoke Ophthalmology’s TONO-i Gains NMPA Approval for Glaucoma Management in China

Fineline Cube Aug 5, 2025

China-based Zhaoke Ophthalmology Limited (HKG: 6622) announced that its innovative product, TONO-i, has received a...

Company Deals

Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau

Fineline Cube Aug 5, 2025

On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with...

Company Drug

Innovent Biologics’ IBI3032 Receives IND Approval From FDA and NMPA for GLP-1RA Clinical Trials

Fineline Cube Aug 5, 2025

China-based Innovent Biologics (HKG: 1801) announced that its self-developed oral small molecule GLP-1 receptor agonist...

Company Deals

Dr. Noah Biotech Collaborates with Thermo Fisher to Accelerate Rare Disease Treatments

Fineline Cube Aug 4, 2025

Korean AI drug discovery company Dr. Noah Biotech has announced the initiation of discussions with...

Company Deals

TenNor Therapeutics Submits Listing Application to Hong Kong Stock Exchange Main Board

Fineline Cube Aug 4, 2025

China-based TenNor Therapeutics (Suzhou) Limited announced the submission of its listing application to the Main...

Company Drug

FDA Clears Elevidys Gene Therapy After Investigating 8-Year-Old Boy’s Death

Fineline Cube Aug 4, 2025

The U.S. Food and Drug Administration (FDA) has completed its investigation into the death of...

Company Drug

Mabwell’s CDH17-Targeted ADC 7MW4911 Receives Clinical Trial Approval in China and IND Clearance in the US

Fineline Cube Aug 4, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that its self-developed CDH17-targeted antibody-drug conjugate...

Company Drug

Cutia Therapeutics’ CU-40102 Approved in Hong Kong for Androgenetic Alopecia Treatment

Fineline Cube Aug 4, 2025

China-based dermatology specialist Cutia Therapeutics (HKG: 2487) announced today that its CU-40102 (finasteride topical spray)...

Company Drug

UTC Therapeutics Gains FDA Clearance for CAR-T Therapy UCLM805 in MSLN-Positive Solid Tumors

Fineline Cube Aug 4, 2025

China-based cell therapy biotech UTC Therapeutics announced receiving clearance from the US Food and Drug...

Company Drug Policy / Regulatory

FDA Mandates Safety Labeling Changes for Opioid Pain Medications and Targets 7-OH Products

Fineline Cube Aug 4, 2025

The U.S. Food and Drug Administration (FDA) is implementing new safety measures for opioid pain...

Company Drug

Luye Pharma’s LY03021 Completes Enrollment of First Healthy Subject in Phase I Trial

Fineline Cube Aug 4, 2025

China-based Luye Pharma Group (HKG: 2186) announced on August 3, 2025, that its self-developed Class...

Company Deals

AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis

Fineline Cube Aug 1, 2025

China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany’s Dr. Falk Pharma GmbH to...

Company Deals

Grand Pharma Partners with IRE EliT to Distribute 68Ge/68Ga Generators in China

Fineline Cube Aug 1, 2025

On July 31, 2025, China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced a strategic collaboration...

Company Drug

Lee’s Pharma’s Socazolimab Approved by NMPA for ES-SCLC First-Line Treatment

Fineline Cube Aug 1, 2025

Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced that its in-licensed programmed-death ligand 1 (PD-L1) monoclonal...

Company Deals

BrightGene and CR Sanjiu Collaborate on BGM0504 Injection Development and Commercialization

Fineline Cube Aug 1, 2025

China-based BrightGene Bio-Medical Technology Co., Ltd. (SHA: 688166) and its affiliated companies announced a collaboration...

Company

AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth

Fineline Cube Aug 1, 2025

US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing...

Posts pagination

1 … 87 88 89 … 634

Recent updates

  • Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market
  • Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing
  • CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces
  • Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic
  • APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Company Drug

Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.